Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an ...

Greenwich LifeSciences (GLSI) announced the following update on FLAMINGO-01 open label safety data. The FLAMINGO-01 DSMB met twice in 2024, ...

Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...

After 5 years of follow-up, there was an 80% or greater reduction in cancer recurrences in the HER2/neu 3+ patients who were treated with GLSI-100, followed, and remained disease free over the ...

Primary neuroendocrine carcinoma of the male breast is an exceptionally rare entity, with fewer than 50 cases documented in ...

HER-Vaxx has been found to stimulate a potent polyclonal antibody response to the cancer target HER-2/neu in preclinical and phase 1 studies. In February, Imugen bagged A$20 million ($12.56 million), ...

Tata Neu and HDFC Bank's co-branded credit card has crossed 2 million issuances, accounting for over 13% of net new credit cards issued in the third quarter of FY25, according to RBI data.

HER2-positive breast cancer, once associated with poor outcomes, now sees improved prognosis due to targeted therapies like Herceptin. Combination therapies and neoadjuvant treatments have enhanced ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Geyer and his colleagues found that among patients with HER2-positive early breast cancer, at a median follow-up of 8.4 years Kadcyla (ado-trastuzumab emtansine) showed sustained improvement in ...